Aniello Cerrato

Institute for Experimental Endocrinology and Oncology — Italy

Medicine · Health Sciences

26h-index2.3kcitations39works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Thyroid Cancer Diagnosis and Treatment(9), Cancer-related Molecular Pathways(8), PARP inhibition in cancer therapy(6), Neuroblastoma Research and Treatments(6), DNA Repair Mechanisms(5)

Publications39 total

Editorial: Combinatorial Approaches for Cancer Treatment: From Basic to Translational Research
Frontiers in Oncology·2022· 8 citedOpen Access
Untargeted metabolomics of prostate cancer zwitterionic and positively charged compound in urine
European Urology·2021
Actinomyces and MRONJ: A retrospective study and a literature review
Journal of Stomatology Oral and Maxillofacial Surgery·2020· 42 cited
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells
Cancers·2019· 7 citedOpen Access
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma
Lung Cancer·2019· 19 cited
Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
International Journal of Molecular Sciences·2019· 36 citedOpen Access
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
Journal of Experimental & Clinical Cancer Research·2019· 60 citedOpen Access
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer
Journal of Experimental & Clinical Cancer Research·2019· 49 citedOpen Access
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
Molecular Cancer·2018· 24 citedOpen Access
CCDC6: the identity of a protein known to be partner in fusion
International Journal of Cancer·2017· 41 citedOpen Access
Wnt/Tcf1 pathway restricts embryonic stem cell cycle through activation of the Ink4/Arf locus
PLoS Genetics·2017· 70 citedOpen Access
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
Oncotarget·2017· 71 citedOpen Access
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Journal of Experimental & Clinical Cancer Research·2016· 119 citedOpen Access
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs
Lung Cancer·2016· 61 cited
FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC
Oncotarget·2015· 48 citedOpen Access
New therapeutic perspectives in <scp>CCDC</scp>6 deficient lung cancer cells
International Journal of Cancer·2014· 52 cited
Chromatin and DNA methylation dynamics during retinoic acid-induced RET gene transcriptional activation in neuroblastoma cells
Nucleic Acids Research·2010· 61 citedOpen Access
CCDC6 represses CREB1 activity by recruiting histone deacetylase 1 and protein phosphatase 1
Oncogene·2010· 41 cited
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
Journal of Molecular Endocrinology·2009· 84 citedOpen Access
<i>IDH1</i>mutations at residue p.R132 (IDH1<sup>R132</sup>) occur frequently in high-grade gliomas but not in other solid tumors
Human Mutation·2009· 366 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Angela Celetti(16), Michèle Grieco(13), Francesco Morra(11), Alfredo Fusco(10), Francesco Merolla(9), Giancarlo Vecchio(8), Roberta Visconti(7), Gennaro Ilardi(6), Stefania Staibano(6), Massimo Santoro(6), Massimo Santoro(5), Sunita Agarwal(4), Francesca Carlomagno(4), Roberto Di Monaco(4), Gianluca Guggino(4), Rosa Marina Melillo(4), Gennaro Chiappetta(3), Domenico Salvatore(3), Giuseppe Portella(3), A. Lee Burns(3)